Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07026279 · ClinicalTrials.gov registry record · Phase 1

A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer

A Phase 1 study of Pancreatic Cancer Metastatic, sponsored by Amplia Therapeutics Limited.

Recruiting
Registry status
Phase 1
Development phase
67
Enrollment target
7
Study locations

NCT07026279: Recruiting Phase 1 study of Pancreatic Cancer Metastatic, sponsored by Amplia Therapeutics Limited.

NCT07026279 is a Phase 1 study of Pancreatic Cancer Metastatic that is actively recruiting participants, run by Amplia Therapeutics Limited. The registered enrollment target is 67 participants, below the 124-participant average among 9 other Pancreatic Cancer Metastatic trials with a reported enrollment target (46% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07026279, a Phase 1 study of Pancreatic Cancer Metastatic, is actively recruiting participants, sponsored by Amplia Therapeutics Limited.

RECRUITING
Registry status
Phase 1
Development phase
67 participants
Enrollment target
7
Study locations

Study Summary

This study is testing narmafotinib, a type of drug called a focal adhesion kinase (FAK) inhibitor, when it is given in combination with 4 chemotherapy drugs in a regimen called FOLFIRINOX, to patients who have pancreatic cancer which has metastasised (spread). The study is being run in 2 parts. Part A will test increasing dose levels of narmafotinib in at least 3 people per dose at up to 4 dose levels to assess safety. Part B will test 2 of the dose levels from Part A in 20 people per dose, to select the best dose to take forward into future studies. Participants will take narmafotinib as oral capsules every day. They will also receive mFOLFIRINOX chemotherapy on Day 1 and and Day 15 of 28-day cycles.

Conditions Studied

Pancreatic Cancer Metastatic

Interventions

  • DRUG narmafotinib ascending doses
  • DRUG narmafotinib dose comparison

Study Locations (7)

California

  • UC Irvine Chao Family Cancer Centre - Orange

Florida

  • University of Florida Shands - Gainesville

New York

  • Icahn School of Medicine at Mount Sinai - New York

Ohio

  • Cleveland Clinic - Cleveland

Tennessee

  • Vanderbilt University Medical Centre - Nashville

New South Wales

  • GenesisCare - St Leonards

Victoria

  • Epworth Healthcare - Richmond

Trial Details

FieldValue
Enrollment Target 67 participants
Start Date 2025-08-18
Est. Completion 2029-07
Phase Phase 1
Amplia Therapeutics Limited

1 total trials

What NCT07026279 shows while recruiting

NCT07026279 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 124-participant average among 9 other Pancreatic Cancer Metastatic trials with a reported enrollment target (46% lower).

The record links to 1 condition, with Pancreatic Cancer Metastatic appearing as the primary indexed condition, and to 2 interventions - of which narmafotinib ascending doses is the first listed.

NCT07026279 lists 7 locations in 7 states (California, Florida, New York).

Frequently Asked Questions

What is clinical trial NCT07026279 about?

NCT07026279 is a clinical study titled "A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer". This study is testing narmafotinib, a type of drug called a focal adhesion kinase (FAK) inhibitor, when it is given in combination with 4 chemotherapy drugs in a regimen called FOLFIRINOX, to patients who have pancreatic cancer which has metastasised (spread). The study is being run in 2 parts. Par...

What is the current status of trial NCT07026279?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2025-08-18. Estimated completion is 2029-07.

What conditions does trial NCT07026279 study?

This clinical trial studies the following conditions: Pancreatic Cancer Metastatic.

What interventions are being tested in trial NCT07026279?

The interventions under investigation include: narmafotinib ascending doses (DRUG), narmafotinib dose comparison (DRUG).

Who is sponsoring clinical trial NCT07026279?

This trial is sponsored by Amplia Therapeutics Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07026279 being conducted?

This trial has 7 study locations across California, Florida, New York, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer Metastatic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07026279's enrollment target sits among peer trials

67 4th of 9 higher than 6 of 9 other Pancreatic Cancer Metastatic trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Cancer Metastatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03213002 · 67 participants · Phase 1

    Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

  • NCT04115163 · 67 participants · Phase 2

    Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

  • NCT04315324 · 67 participants · Phase 1

    Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

  • NCT04532424 · 67 participants · NA

    Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07026279

Source: ClinicalTrials.gov NCT07026279, the US trial registry maintained by the National Library of Medicine. NCT07026279 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.